Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Operating Income history
Currency unavailable · from the income statement
No Operating Income data reported for this period type.
Operating Income vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $58.34M USD | +143.3% | — | 20.7% | |
| LTM Mar 2026 | $40.8M USD | +140.7% | — | 17.6% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | -€48.02M EUR | -54.0% | — | — |
| LTM Mar 2026 | -$80.48M USD | +43.0% | — | 961.9% | |
| LTM Mar 2026 | -$109.64M USD | -8.6% | — | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$183.11M USD | -45.4% | — | — |
| LTM Sep 2026 | -$250.17M USD | -17.1% | — | 276.5% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$459M USD | -4.5% | — | 6204.4% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ODTX) | — | -6.5% | — | 276.5% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.